Home
BIO
BIO News

Latest Bio-Rad Laboratories Inc. (BIO) News on March 30, 2025

Argus Research

5 days ago

BIO: Rating decreased to a SELL

Alger Russell Innovation Index Updates for First Quarter 2025

PR Newswire

13 days ago

Alger Russell Innovation Index Updates for First Quarter 2025

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Simply Wall St.

23 days ago

Bio-Rad Laboratories, Inc. (NYSE:BIO) is a favorite amongst institutional investors who own 60%

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

Insider Monkey

25 days ago

Is Bio-Rad Laboratories, Inc. (BIO) the Best Medical Technology Stock to Buy According to Analysts?

Argus Research

a month ago

BIO: Lowering target price to $263.00

Bio-Rad (BIO) International Revenue Performance Explored

Zacks

a month ago

Bio-Rad (BIO) International Revenue Performance Explored

Argus Research

a month ago

BIO: Lowering target price to $291.00

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Zacks

a month ago

HSIC Q4 Earnings Match Estimates, Margins Up, Stock Falls in Premarket

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Zacks

a month ago

Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

Zacks

a month ago

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Zacks

a month ago

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Zacks

a month ago

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Argus Research

a month ago

BIO: Rating increased to a HOLD

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

Zacks

a month ago

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

Zacks

a month ago

BIO Stock Might Rise Following the Offer to Acquire Stilla

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

a month ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Bio-Rad price target lowered to $447 from $477 at RBC Capital

TipRanks

a month ago

Bio-Rad price target lowered to $447 from $477 at RBC Capital

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

a month ago

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Morningstar Research

a month ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Zacks

a month ago

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad set to acquire Stilla Technologies

Medical Device Network

a month ago

Bio-Rad set to acquire Stilla Technologies

Morningstar Research

a month ago

Analyst Report: Bio-Rad Laboratories, Inc.

MT Newswires

a month ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating

MT Newswires

a month ago

RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating

Thomson Reuters StreetEvents

a month ago

Q4 2024 Bio Rad Laboratories Inc Earnings Call

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Zacks

a month ago

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com

a month ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Zacks

a month ago

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Associated Press Finance

a month ago

Bio-Rad: Q4 Earnings Snapshot

MT Newswires

a month ago

Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Zacks

2 months ago

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

GuruFocus.com

2 months ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

OncoCyte prices $29.1M equity offering

TipRanks

2 months ago

OncoCyte prices $29.1M equity offering

Oncocyte Prices $29.1 Million Equity Offering

GlobeNewswire

2 months ago

Oncocyte Prices $29.1 Million Equity Offering

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

Zacks

2 months ago

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

Zacks

2 months ago

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Zacks

2 months ago

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks

2 months ago

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

Zacks

2 months ago

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

Argus Research

2 months ago

BIO: Lowering target price to $279.00

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks

2 months ago

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

MT Newswires

2 months ago

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

Argus Research

2 months ago

BIO: Raising target price to $294.00

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Insider Monkey

2 months ago

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Business Wire

2 months ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Argus Research

2 months ago

BIO: Lowering target price to $283.00

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Zacks

2 months ago

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Zacks

2 months ago

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Argus Research

3 months ago

BIO: Raising target price to $294.00

MT Newswires

3 months ago

Bio-Rad Laboratories Led $105 Million Series C Funding Round for Geneoscopy

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Business Wire

3 months ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Business Wire

3 months ago

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Simply Wall St.

3 months ago

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Argus Research

3 months ago

BIO: Rating increased to a HOLD

Argus Research

3 months ago

BIO: Lowering target price to $277.00

Argus Research

4 months ago

BIO: Lowering target price to $278.00

MT Newswires

4 months ago

RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating

Argus Research

4 months ago

BIO: Raising target price to $291.00

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Zacks

4 months ago

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Simply Wall St.

4 months ago

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Insider Monkey

4 months ago

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Business Wire

4 months ago

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?

Insider Monkey

5 months ago

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?

Argus Research

5 months ago

BIO: Lowering target price to $292.00

Argus Research

5 months ago

BIO: Raising target price to $299.00

Interpreting Bio-Rad (BIO) International Revenue Trends

Zacks

5 months ago

Interpreting Bio-Rad (BIO) International Revenue Trends

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St.

5 months ago

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Simply Wall St.

5 months ago

Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Thomson Reuters StreetEvents

5 months ago

Q3 2024 Bio Rad Laboratories Inc Earnings Call

Morningstar Research

5 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

MT Newswires

5 months ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Business Wire

5 months ago

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Zacks

5 months ago

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...

GuruFocus.com

5 months ago

Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Zacks

5 months ago

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Associated Press Finance

5 months ago

Bio-Rad: Q3 Earnings Snapshot

Bio-Rad Reports Third-Quarter 2024 Financial Results

Business Wire

5 months ago

Bio-Rad Reports Third-Quarter 2024 Financial Results

What to Expect From These 3 MedTech Stocks This Earnings Season

Zacks

5 months ago

What to Expect From These 3 MedTech Stocks This Earnings Season

Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week

Simply Wall St.

5 months ago

Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Zacks

5 months ago

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?

Zacks

5 months ago

FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?

BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Zacks

5 months ago

BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund

Insider Monkey

6 months ago

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Business Wire

6 months ago

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

BANK OF NOVA SCOTIA's Strategic Acquisition in Bio-Rad Laboratories Inc

GuruFocus.com

6 months ago

BANK OF NOVA SCOTIA's Strategic Acquisition in Bio-Rad Laboratories Inc

Argus Research

6 months ago

BIO: Raising target price to $274.00

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Zacks

6 months ago

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

MT Newswires

6 months ago

Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350

Palantir Soars, Dell Pops As Big AI Plays Finally Get S&P 500 Nod

Investor's Business Daily

7 months ago

Palantir Soars, Dell Pops As Big AI Plays Finally Get S&P 500 Nod

Palantir and Dell Will Join S&P 500—What You Need To Know

Investopedia

7 months ago

Palantir and Dell Will Join S&P 500—What You Need To Know

Palantir Stock Jumps on S&P 500 Addition. Here’s Who Else Was Added.

Barrons.com

7 months ago

Palantir Stock Jumps on S&P 500 Addition. Here’s Who Else Was Added.

Palantir, Dell Will Finally Join The S&P 500. The Stocks Are Jumping.

Investor's Business Daily

7 months ago

Palantir, Dell Will Finally Join The S&P 500. The Stocks Are Jumping.

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PR Newswire

7 months ago

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Palantir, Dell Stocks Jump on S&P 500 Addition

Barrons.com

7 months ago

Palantir, Dell Stocks Jump on S&P 500 Addition

National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?

Zacks

7 months ago

National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?

MT Newswires

7 months ago

Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target

Argus Research

7 months ago

BIO: Raising target price to $283.00

Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference

Business Wire

7 months ago

Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Zacks

7 months ago

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Argus Research

7 months ago

BIO: What does Argus have to say about BIO?

Share on Social Networks: